Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-TET2 Antibody (R3Y66)

Catalog #:   RHK23701 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM
Accession: Q6N021
Overview

Catalog No.

RHK23701

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400

Target

KIAA1546, TET2, Methylcytosine dioxygenase TET2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q6N021

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3Y66

Data Image
  • Flow Cytometry
    Flow cytometric analysis of Hela cells using TET2 mouse mAb (green) and negative control (red).
References

Biological and Clinical Relevance of Genetic Alterations in Peripheral T-cell Lymphomas., PMID:40416001

Genetic determinants of proteomic aging., PMID:40287427

TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment., PMID:40111422

Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody., PMID:39984633

Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD., PMID:39899881

Glucocorticoid promotes metastasis of colorectal cancer via co-regulation of glucocorticoid receptor and TET2., PMID:39661335

Clonal hematopoiesis and atherosclerosis., PMID:39352379

Long-term longitudinal analysis of 4,187 participants reveals insights into determinants of clonal hematopoiesis., PMID:39251642

A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL., PMID:38983865

Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?, PMID:38884213

Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial., PMID:38701435

Loss of TET2 increases B-1 cell number and IgM production while limiting CDR3 diversity., PMID:38601144

Suppression of IL-1β promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis., PMID:38362011

Germline and Somatic Mutations in DNA Methyltransferase 3A (DNMT3A) Predispose to Pulmonary Arterial Hypertension (PAH) in Humans and Mice: Implications for Associated PAH., PMID:38234783

miR-17-92 cluster-BTG2 axis regulates B-cell receptor signaling in mantle cell lymphoma., PMID:38050664

Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis., PMID:38049983

HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment., PMID:37985171

Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial., PMID:37934948

Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?, PMID:37915324

Clearing and replacing tissue-resident myeloid cells with an anti-CD45 antibody-drug conjugate., PMID:37748049

CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer., PMID:37732224

Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis., PMID:37539077

Genetic modification of inflammation- and clonal hematopoiesis-associated cardiovascular risk., PMID:37498674

Pathologic and molecular insights in nodal T-follicular helper cell lymphomas., PMID:36793612

Epigenetic remodeling by vitamin C potentiates plasma cell differentiation., PMID:36069787

Clonal germinal center B cells function as a niche for T-cell lymphoma., PMID:35921527

Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review., PMID:35818539

Synthetic libraries of immune cells displaying a diverse repertoire of chimaeric antigen receptors as a potent cancer immunotherapy., PMID:35668107

Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality., PMID:35625998

Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience., PMID:35392224

TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial., PMID:35385050

Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic., PMID:35318270

Cordyceps militaris extract induces apoptosis and pyroptosis via caspase-3/PARP/GSDME pathways in A549 cell line., PMID:35035907

Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia., PMID:34903734

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia., PMID:34847227

Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation., PMID:34793200

Tet2 deficiency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model., PMID:34657351

Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management., PMID:34447369

Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis., PMID:34258102

Genomic Landscape of Chinese Clear Cell Renal Cell Carcinoma Patients With Venous Tumor Thrombus Identifies Chromosome 9 and 14 Deletions and Related Immunosuppressive Microenvironment., PMID:34249685

Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite Lymphoma Potentially Mimicking Richter Syndrome., PMID:33739791

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma., PMID:33496747

TET3 dioxygenase modulates gene conversion at the avian immunoglobulin variable region via demethylation of non-CpG sites in pseudogene templates., PMID:33421268

Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma., PMID:33376237

Ascorbic Acid Promotes Plasma Cell Differentiation through Enhancing TET2/3-Mediated DNA Demethylation., PMID:33264617

PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab., PMID:33246647

TET2 chemically modifies tRNAs and regulates tRNA fragment levels., PMID:33230319

Functional role of Tet-mediated RNA hydroxymethylcytosine in mouse ES cells and during differentiation., PMID:33009383

TET2 promotes anti-tumor immunity by governing G-MDSCs and CD8+ T-cell numbers., PMID:32929842

The angiocrine Rspondin3 instructs interstitial macrophage transition via metabolic-epigenetic reprogramming and resolves inflammatory injury., PMID:32839607

Datasheet

Document Download

Anti-TET2 Antibody (R3Y66).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-TET2 Antibody (R3Y66) [RHK23701]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only